Metal Metabolism, Inborn Errors: Clinical Trials

29 trials for Metal Metabolism, Inborn Errors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 3 active not recruiting, 3 terminated, 3 unknown. 29 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 329Completed 19, Active not recruiting 3, Terminated 3, Unknown 3, Recruiting 1
Phase 22Completed 2

Follow Metal Metabolism, Inborn Errors: new trials by email Literature Review of Metal Metabolism, Inborn Errors trials Research Report on Metal Metabolism, Inborn Errors

Trials (filtered) newest first · largest first

All 29 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
TETA 4HCl formulation, D-Penicillamine - Wilson's Disease
Phase 3RecruitingOrphalan382026-09-032026-10-15
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
ALXN1850, Placebo - Hypophosphatasia
Phase 3Active not recruitingAlexion Pharmaceuticals, Inc.302024-05-142026-05-28
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
ALXN1850, asfotase alfa - Hypophosphatasia
Phase 3Active not recruitingAlexion Pharmaceuticals, Inc.432024-04-022026-05-05
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
ALXN1850, Placebo - Hypophosphatasia
Phase 3Active not recruitingAlexion Pharmaceuticals, Inc.1242024-01-032026-06-22
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
ALXN1840, Standard of Care - Wilson Disease
Phase 3TerminatedAlexion Pharmaceuticals, Inc.402021-09-132024-10-23
Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT
adhesive system, fluoride varnish, flowable composite - X-linked Hypophosphatemia (XLH)
Phase 3UnknownAssistance Publique - Hôpitaux de Paris602021-06-012021-05-05
Anti-FGF23 (Burosumab) in Adult Patients With XLH
Burosumab - X-linked Hypophosphatemia
Phase 3CompletedWuerzburg University Hospital362021-01-072023-05-03
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
Burosumab - X-linked Hypophosphatemia
Phase 3CompletedKyowa Kirin Pharmaceutical Development Ltd352019-03-072022-05-20
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Penicillamine (D1-W12), TETA 4HCL (W12-60), Penicillamine (W12-W60) - Wilson Disease
Phase 3CompletedOrphalan772018-09-032025-07-02
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
ALXN1840, SoC Therapy - Wilson Disease
Phase 3TerminatedAlexion Pharmaceuticals, Inc.2142018-02-222024-06-17
A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
KRN23 - X-linked Hypophosphatemic Rickets/Osteomalacia
Phase 3CompletedKyowa Kirin Co., Ltd.162017-07-062022-09-06
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
burosumab, Oral Phosphate Supplement, active vitamin D - X-Linked Hypophosphatemia
Phase 3CompletedKyowa Kirin, Inc.612016-09-082024-08-29
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
burosumab - X-linked Hypophosphatemia
Phase 3CompletedKyowa Kirin, Inc.142015-12-232024-06-18
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
burosumab, Placebo - X-linked Hypophosphatemia
Phase 3CompletedKyowa Kirin, Inc.1342015-10-222024-06-18
Lamotrigine as Treatment of Myotonia
Lamotrigine, Placebo - Dystrophia Myotonica Type 1, Myotonia Congenita
Phase 3CompletedGrete Andersen, MD272013-11-012016-04-25
Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)
G.S.P. Oral Solution 400 mg/ml - Galactose Single Point (GSP), Residual Liver Function
Phase 3UnknownRichever Enterprise Co., Ltd.2002013-09-092018-03-07
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
asfotase alfa - Hypophosphatasia
Phase 2 / Phase 3CompletedAlexion Pharmaceuticals, Inc.692010-07-012019-03-13
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Copper Histidine - Menkes Disease, Occipital Horn Syndrome
Phase 3CompletedCyprium Therapeutics, Inc.932009-02-272020-11-19
Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients
Phlebotomy and erythrocytapheresis - Hereditary Hemochromatosis
Phase 3UnknownSanquin Research & Blood Bank Divisions402008-05-012013-12-04
Hyper- and Hypokalemic Periodic Paralysis Study
Dichlorphenamide (double-blind), Placebo (double-blind), Dichlorphenamide (open-label) - Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis
Phase 3CompletedUniversity of Rochester712007-06-012017-06-14

Showing 20 of 29. Sign in to see all of them.

Narrower conditions

Familial Hypophosphatemic Rickets (8)  ·  Hemochromatosis (6)  ·  Hepatolenticular Degeneration (6)  ·  Hypophosphatasia (4)  ·  Paralysis, Hyperkalemic Periodic (3)  ·  Hypokalemic Periodic Paralysis (2)  ·  Myotonic Disorders (2)  ·  Osteomalacia (2)  ·  Rare Diseases (2)  ·  Rickets (2)  ·  Anemia, Sickle Cell (1)  ·  Bone Diseases (1)  ·  Carcinoma, Hepatocellular (1)  ·  Fibrosis (1)  ·  Hematologic Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (29)  ·  Genetic Diseases, Inborn (29)  ·  Metabolic Diseases (29)  ·  Nutritional and Metabolic Diseases (29)  ·  Metabolism, Inborn Errors (28)  ·  Musculoskeletal Diseases (13)  ·  Nervous System Diseases (11)  ·  Bone Diseases, Metabolic (10)  ·  Calcium Metabolism Disorders (10)  ·  Avitaminosis (9)  ·  Bone Diseases (9)  ·  Deficiency Diseases (9)  ·  Malnutrition (9)  ·  Nutrition Disorders (9)

Interventions

burosumab (6)  ·  Phlebotomy (3)  ·  Dichlorphenamide (2)  ·  Penicillamine (2)  ·  asfotase alfa (2)  ·  tetrathiomolybdate (2)  ·  Bloodletting (1)  ·  Deferiprone (1)  ·  Deferoxamine (1)  ·  Double-Blind Method (1)  ·  Erythrocyte Transfusion (1)  ·  Hydroxyurea (1)  ·  Iron Chelating Agents (1)  ·  Lamotrigine (1)  ·  Long Interspersed Nucleotide Elements (1)

Sponsors

Alexion Pharmaceuticals, Inc. (6)  ·  Kyowa Kirin, Inc. (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  National Center for Research Resources (NCRR) (2)  ·  Orphalan (2)  ·  Sanquin Research & Blood Bank Divisions (2)  ·  Cyprium Therapeutics, Inc. (1)  ·  Grete Andersen, MD (1)  ·  Kyowa Kirin Co., Ltd. (1)  ·  Kyowa Kirin Pharmaceutical Development Ltd (1)  ·  Lipomed (1)  ·  Nobelpharma (1)  ·  Richever Enterprise Co., Ltd. (1)  ·  San Filippo Neri General Hospital (1)  ·  St. Jude Children's Research Hospital (1)

Countries

United States (15)  ·  United Kingdom (10)  ·  France (9)  ·  Japan (9)  ·  Australia (7)  ·  Canada (7)  ·  Italy (7)  ·  Germany (6)  ·  South Korea (6)  ·  Turkey (Türkiye) (6)  ·  Poland (5)  ·  Spain (5)  ·  Denmark (4)  ·  Brazil (3)  ·  China (3)

Top investigators

Eva Rombout, MD (2)  ·  Amal M El-Beshlawy, Prof. Dr. (1)  ·  Eugene S. Swenson, M.D., Ph.D. (1)  ·  Eugene S. Swenson, MD, PhD (1)  ·  Francesco Equitani, M.D. (1)  ·  George J. Brewer (1)  ·  Grete Andersen, MD (1)  ·  Jean-Claude Trinchet, Pr, MD, PhD (1)  ·  Jerry R. Mendell (1)  ·  Koudou Ishii, M.D. (1)  ·  Lothar Seefried, MD (1)  ·  Michael McDermott, Ph.D. (1)  ·  Peter Kamenicky (1)  ·  Rabi Tawil, M.D. (1)

Results publications

PMID 39151033, PMID 36854566, PMID 17959863, PMID 18055982, PMID 18351337, PMID 21078496, PMID 21826782, PMID 21848963, PMID 22144108, PMID 22180427, PMID 22318199, PMID 23861242, PMID 24914136, PMID 25029424, PMID 25284616, PMID 26529632, PMID 29947083, PMID 30811537, PMID 31104833, PMID 31165191, PMID 32721016, PMID 32762706, PMID 33368569, PMID 33484279, PMID 34522876, PMID 34548383, PMID 35533340, PMID 35775373, PMID 35927518, PMID 36183738, PMID 36719566, PMID 37084401, PMID 39139457, PMID 41831608

NIH funding

2014 (1), 2017 (1), P50AR054086 (1), U01HL078787 (1)